Soft Tissue Sarcoma Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Soft Tissue Sarcoma market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals

[Nevada, United States] - DelveInsight's "Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast 2032." report offers a detailed examination of Soft Tissue Sarcoma, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Soft Tissue Sarcoma Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Soft Tissue Sarcoma Market Report:
The Soft Tissue Sarcoma market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).
In October, 2024: Epizyme, Inc. announced that the participants of their study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue.
In October, 2024: Immunophotonics, Inc. announced that the goal of their trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
In October, 2024: Eli Lilly and Company announced that the purpose of their study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolamide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer.
In October, 2024: Servier Bio-Innovation LLC announced that CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection.
In October, 2024: Merck Sharp & Dohme LLC announced that Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
According to Popovich et al. (2022), STS are a rare entity, and they account for approximately 1% of all cancer incidence in the US, and represent approximately 2% of cancer-related deaths.
As per the Bone and Soft Tissue Tumor (BSTT) registry of Japan (2022), the age standardized incidence rate of STS is expected to increase from 4.48 to 5.32 per 100,000 in the coming years.
As per a study by Liu et al. (2022), the incidence of STS varies in different countries and regions, with a crude incidence of 4.7 per 100,000 in Europe and an overall incidence of 7.1 cases per 100,000 people in the US.
Key Soft Tissue Sarcoma Companies are as follows: Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals
Key Soft Tissue Sarcoma Therapies are as follow: Tazemetostat, Doxorubicin, Tazemetostat, 1.0% IP-001 for Injection, Abemaciclib, Irinotecan, Temozolomide, Ivosidenib, Zilovertamab vedotin, Nanatinostat, Eribulin, Dostarlimab, Lurbinectedin, Doxorubicin, Brigimadlin, Doxorubicin, Cabozantinib, Palbociclib, Temozolomide, Irinotecan, ION363, Tabelecleucel, CYT-0851, RAD001, ELI-002 7P
Launching multiple stage Soft Tissue Sarcoma pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Soft Tissue Sarcoma market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Soft Tissue Sarcoma Overview:
Soft tissue sarcoma refers to a group of rare cancers that originate in the soft tissues of the body, such as muscles, fat, nerves, tendons, and blood vessels. Sarcomas are a diverse group of tumors that can develop in various locations and can be classified based on the specific type of soft tissue cell they arise from.

Soft Tissue Sarcoma Epidemiology Segmentation:
The Soft Tissue Sarcoma market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
Soft Tissue Sarcoma Total Incident Cases
Soft Tissue Sarcoma Prevalence by Extremity in the US
Soft Tissue Sarcoma Stage-specific Incident Cases
Soft Tissue Sarcoma Type-specific Incident Cases

For more information about Soft Tissue Sarcoma companies working in the treatment market, visit https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Soft Tissue Sarcoma Market Insights
The soft tissue sarcoma market is anticipated to expand considerably over the next decade. Factors contributing to this growth include the rising incidence of soft tissue sarcomas, advancements in diagnostic techniques, and a robust pipeline of new drugs. Key countries in this market include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan, with each demonstrating distinct market dynamics and patient demographics

Soft Tissue Sarcoma Drugs Uptake
Yondelis (Trabectedin): This drug is derived from a marine organism and acts by preventing tumor cell growth. It has demonstrated efficacy in treating advanced soft tissue sarcoma
Lartruvo (Olaratumab): Approved for use in combination with doxorubicin, this drug is aimed at treating soft tissue sarcoma and is known for enhancing patient outcomes
Votrient (Pazopanib): This targeted therapy is used to treat certain types of soft tissue sarcomas and has been effective in managing disease progression
TECENTRIQ (atezolizumab) developed by Genentech was approved in 2022for the treatment of adult and pediatric patients two years of age and olderwith unresectable or metastatic alveolar soft part sarcoma (ASPS).
AYVAKIT (avapritinib) is a kinase inhibitor approved in 2020 by the FDA forthe treatment of adults with unresectable or metastatic GIST harboring aPDGFRA exon 18 mutation, including PDGFRA D842V mutations.
TAZVERIK (tazemetostat) is indicated for the treatment of adults andpediatric patients aged 16 years and older with metastatic or locallyadvanced epithelioid sarcoma not eligible for complete resection.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Soft Tissue Sarcoma Therapies and Key Companies:
Tazemetostat, Doxorubicin, Tazemetostat: Epizyme, Inc.
1.0% IP-001 for Injection: Immunophotonics, Inc.
Abemaciclib, Irinotecan, Temozolomide: Eli Lilly and Company
Ivosidenib: Servier Bio-Innovation LLC
Zilovertamab vedotin: Merck Sharp & Dohme LLC
Nanatinostat; Viracta Therapeutics, Inc.
Eribulin: Italian Sarcoma Group
Dostarlimab: UNICANCER
Lurbinectedin, Doxorubicin: PharmaMar
Brigimadlin, Doxorubicin: Boehringer Ingelheim
Cabozantinib: Ipsen
Palbociclib, Temozolomide, Irinotecan: Pfizer
ION363: Ionis Pharmaceuticals, Inc.
Tabelecleucel: Atara Biotherapeutics
CYT-0851: Cyteir Therapeutics, Inc.
RAD001: Novartis Pharmaceuticals
ELI-002 7P: Elicio Therapeutics

Soft Tissue Sarcoma Epidemiology:
Soft tissue sarcomas (STS) are a heterogeneous group of malignancies originating in connective tissues, including muscles, fat, nerves, and blood vessels. They account for about 1% of all adult cancers and are more prevalent in younger adults and children. The estimated incidence of STS varies by geography, but globally, it is approximately 4 to 5 cases per 100,000 people annually​

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Soft Tissue Sarcoma Market Drivers:
Increasing Incidence and Awareness
Innovative Therapeutic Options
Research and Development Investments
Improved Treatment Guidelines

Soft Tissue Sarcoma Market Barriers:
High Treatment Costs
Limited Awareness and Misdiagnosis
Challenges in Clinical Trials

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Soft Tissue Sarcoma Market Report:
Study Period: 2019-2032
Coverage: 7MM (The United States, EU5, and Japan)
Key Soft Tissue Sarcoma Companies: Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals
Key Soft Tissue Sarcoma Therapies: Tazemetostat, Doxorubicin, Tazemetostat, 1.0% IP-001 for Injection, Abemaciclib, Irinotecan, Temozolomide, Ivosidenib, Zilovertamab vedotin, Nanatinostat, Eribulin, Dostarlimab, Lurbinectedin, Doxorubicin, Brigimadlin, Doxorubicin, Cabozantinib, Palbociclib, Temozolomide, Irinotecan, ION363, Tabelecleucel, CYT-0851, RAD001, ELI-002 7P
Soft Tissue Sarcoma Therapeutic Assessment: Current marketed and emerging therapies
Soft Tissue Sarcoma Market Dynamics: Soft Tissue Sarcoma Market drivers and Soft Tissue Sarcoma barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Soft Tissue Sarcoma Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Soft Tissue Sarcoma market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Executive Summary of Soft Tissue Sarcoma
3. Competitive Intelligence Analysis for Soft Tissue Sarcoma
4. Soft Tissue Sarcoma: Market Overview at a Glance
5. Soft Tissue Sarcoma: Disease Background and Overview
6. Patient Journey
7. Soft Tissue Sarcoma Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Soft Tissue Sarcoma Unmet Needs
10. Key Endpoints of Soft Tissue Sarcoma Treatment
11. Soft Tissue Sarcoma Marketed Products
12. Soft Tissue Sarcoma Emerging Therapies
13. Soft Tissue Sarcoma: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Soft Tissue Sarcoma
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2024

Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.